Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Long-term Debt

Borrowings due after more than one year.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 58.1% from a year ago

Long-term debt stood at $2.48M at the end of Q1 FY2026, down 58.1% from a year earlier and down 9.2% from the prior quarter. Over 3 fiscal years it compounded at -54.6% a year.

Context

  • Long-term debt amounted to 4.8% of total assets at the end of Q1 FY2026, down 19.8 pp from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -58.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.48M-9.2% QoQ
Last fiscal yearDec 2025
$2.73M-71.6% YoY
Year agoMar 2025
$5.92M-58.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.1%——
1 year-71.6%——
3-year CAGR-54.6%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
2.73M USD
Year-over-year change
-71.6%

Long-term Debt vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -58.1% is the lowest of 3, against a peer median of +56.4%.
  • Long-term debt amounts to 4.8% of total assets for RANI, versus a peer median of 0.2%.
RANI Competitors
Long-term Debt for RANI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MISTMilestone Pharmaceuticals Inc.Mar 2026$136.3M USD+151.1%—70.4%
IPHAInnate Pharma S.A.Dec 2025€13.67M EUR-38.4%-29.4%21.8%
ELTXElicio Therapeutics, Inc.Mar 2026$9.48M USD——41.8%
RANIRani Therapeutics Holdings, Inc.Mar 2026$2.48M USD-58.1%-54.6%4.8%
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026$1.13M USD——0.4%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 USD——0.0%
CRDFCardiff Oncology, Inc.Mar 2026$0 USD——0.0%
SGMOSangamo Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding RANI) —+56.4%-29.4%0.2%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.45M27.01M5.86M3.76M18.62M
Short-term Investments071.48M42.68M23.88M31.09M
Net Receivables00200K428K2.04M
Inventory00000
Other Current Assets0500K800K1.68M1.57M
Total Current Assets119.6M100.92M50.85M29.74M53.32M
Property, Plant & Equipment (Net)4.61M7.1M6.82M6.64M5.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00246K246K246K
Total Non-current Assets4.61M7.1M7.07M6.89M5.3M
Total Assets124.21M108.03M57.92M36.63M58.62M
Account Payables1.08M1.46M648K1.36M309K
Short-term Debt004.9M15M0
Tax Payables00000
Deferred Revenue001.21M06.83M
Other Current Liabilities398K591K202K283K46K
Total Current Liabilities2.64M4.82M7.99M19.89M12.67M
Long-term Debt029.15M24.48M9.61M2.73M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.71M
Other Non-current Liabilities00000
Total Non-current Liabilities029.21M24.48M13.25M4.44M
Total Liabilities2.64M34.02M32.47M33.14M17.11M
Common Stock5K5K5K5K11K
Retained Earnings(8.33M)(38.92M)(72.89M)(102.91M)(132.58M)
Accumulated OCI(0)(73K)(12K)5K1K
Other Stockholders Equity(2)0000
Minority Interest74.16M37.15M12.58M1.5M8.5M
Total Equity121.57M74M25.44M3.49M41.51M
Total Debt030.21M30.1M29.71M4.32M
Net Debt(117.45M)3.21M24.24M25.95M(14.3M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.